Osteoporosis (OP) is a systemic skeletal disease characterized by decreased bone density and deteriorated bone microarchitecture, leading to increased bone fragility and susceptibility to fracture.

Globally, more than 200 million people are affected, and in China the patient population is estimated at approximately 90 million.

Current anabolic therapies for OP mainly comprise recombinant human parathyroid hormone analogues—such as teriparatide (rhPTH[1–34]) and abaloparatide (PTHrP)—and the sclerostin monoclonal antibody romosozumab (Evenity).

But these agents have notable limitations and risks. For example, long-term use of teriparatide has been associated with an increased risk of osteosarcoma in animal studies. Romosozumab, while potent, carries a boxed warning for serious cardiovascular events.

Therefore, the development of next-generation osteoanabolic peptides—engineered for superior safety and sustained efficacy—has become a critical unmet medical need for millions of patients living with osteoporosis.